Spyre Therapeutics, Inc. (NASDAQ: SYRE) announced the launch of its SPY772 combination program and the initiation of a Phase 2 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE